Analyst consensus rating
Atrium Therapeutics Analyst Rating: none
Direct answer
Atrium Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.00.
Forecast evidence checked September 3, 2026.
Get free Atrium Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.60
- Average price target
- $25.00
- High price target
- $25.00
- Low price target
- $25.00
- Low target gap
- +71.2%
- Target upside
- +71.2%
- High target gap
- +71.2%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 3, 2026
- Valid through
- September 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Atrium Therapeutics?
Atrium Therapeutics has a verified none consensus. The same dataset has an average price target of $25.00.
How far are Atrium Therapeutics's low and high targets from the recorded price?
The low target implies +71.2%, while the high target implies +71.2%.
How many analysts are included in Atrium Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Atrium Therapeutics's target upside or downside calculated?
The average target of $25.00 is divided by the recorded price of $14.60, then one is subtracted to produce +71.2%. This does not guarantee a future return.
When was Atrium Therapeutics's analyst forecast verified?
The data was verified on 2026-09-03. The dataset is valid through 2026-09-10.